Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan J Sullivan

Showing results (31-40 of 326) with videos related to

Pageof 33
Sort By:
Nature Reviews. Drug Discovery|July 28, 2021
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategiesRyan J Sullivan, Jeffrey S Weber
Cancer|June 22, 2023
The case for adjuvant BRAF-targeted therapy versus adjuvant anti-PD-1 therapy for patients with resected, high-risk melanomaMeghan J Mooradian, Ryan J Sullivan
European Journal of Cancer (Oxford, England : 1990)|January 8, 2013
Resistance to BRAF-targeted therapy in melanomaRyan J Sullivan, Keith T Flaherty
Hematology/Oncology Clinics of North America|June 2, 2014
Understanding the biology of melanoma and therapeutic implicationsRyan J Sullivan, David E Fisher
Oncology (Williston Park, N.Y.)|April 17, 2019
What to Do When Anti-PD-1 Therapy Fails in Patients With MelanomaMeghan J Mooradian, Ryan J Sullivan
Melanoma Management|September 8, 2018
Biomarkers in melanoma: where are we now?Douglas B Johnson, Ryan J Sullivan
Melanoma Management|September 8, 2018
Are we entering the era of combination therapy for melanoma?Justine V Cohen, Ryan J Sullivan
Cancers|August 26, 2023
Immunotherapy in Melanoma: Recent Advancements and Future DirectionsMeghan J Mooradian, Ryan J Sullivan
Drug Design, Development and Therapy|February 14, 2023
Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special ConsiderationsKamaneh Montazeri, Vikram Pattanayak, Ryan J Sullivan
Cancers|November 27, 2025
KIT-Mutant Melanoma: Understanding the Pathway to Personalized TherapyAditi Kaveti, Ryan J Sullivan, Hensin Tsao
Pageof 33

Showing results (31-40 of 326) with videos related to

Sort By:
Pageof 33
Nature Reviews. Drug Discovery|July 28, 2021
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategiesRyan J Sullivan, Jeffrey S Weber
Cancer|June 22, 2023
The case for adjuvant BRAF-targeted therapy versus adjuvant anti-PD-1 therapy for patients with resected, high-risk melanomaMeghan J Mooradian, Ryan J Sullivan
European Journal of Cancer (Oxford, England : 1990)|January 8, 2013
Resistance to BRAF-targeted therapy in melanomaRyan J Sullivan, Keith T Flaherty
Hematology/Oncology Clinics of North America|June 2, 2014
Understanding the biology of melanoma and therapeutic implicationsRyan J Sullivan, David E Fisher
Oncology (Williston Park, N.Y.)|April 17, 2019
What to Do When Anti-PD-1 Therapy Fails in Patients With MelanomaMeghan J Mooradian, Ryan J Sullivan
Melanoma Management|September 8, 2018
Biomarkers in melanoma: where are we now?Douglas B Johnson, Ryan J Sullivan
Melanoma Management|September 8, 2018
Are we entering the era of combination therapy for melanoma?Justine V Cohen, Ryan J Sullivan
Cancers|August 26, 2023
Immunotherapy in Melanoma: Recent Advancements and Future DirectionsMeghan J Mooradian, Ryan J Sullivan
Drug Design, Development and Therapy|February 14, 2023
Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special ConsiderationsKamaneh Montazeri, Vikram Pattanayak, Ryan J Sullivan
Cancers|November 27, 2025
KIT-Mutant Melanoma: Understanding the Pathway to Personalized TherapyAditi Kaveti, Ryan J Sullivan, Hensin Tsao
Pageof 33